VCYT
Veracyte, Inc.Healthcare · $3.7B market cap
Verdict
We can't put a fair value on VCYT right now. It has fewer than 5 profitable years and uneven cash flow, not enough history to project from yet.
Business quality
4 of 5 clear the 10% bar. What are the Big Five?
Follow VCYT
Track it on your watchlist and see the full analysis. Free.
Create a free accountInsider activity
Since Sep 1, 2026: no open-market purchases, 7 sales worth $942K and 6 other filings (stock awards, tax withholding and similar). Why purchases matter
Sales
McGuire Annie
EVP, General Counsel · 2026-09-04
Sold
$48K
McGuire Annie
EVP, General Counsel · 2026-09-04
Sold
$92K
Chambers Rebecca
Chief Financial Officer · 2026-09-04
Sold
$51K
Chambers Rebecca
Chief Financial Officer · 2026-09-04
Sold
$106K
Febbo Phillip G.
Chief Scientific & Med Officer · 2026-09-04
Sold
$118K
Other filings
Stapley Marc
Chief Executive Officer · 2026-09-02
Tax withholding
$394K
McGuire Annie
EVP, General Counsel · 2026-09-02
Tax withholding
$144K
Chambers Rebecca
Chief Financial Officer · 2026-09-02
Tax withholding
$162K
Febbo Phillip G.
Chief Scientific & Med Officer · 2026-09-02
Tax withholding
$163K
Leite John
Global Chief Commercial Off · 2026-09-02
Tax withholding
$178K
Show all 6 other filingsShow fewer
Wygant Jonathan
VP, Chief Accounting Officer · 2026-09-02
Tax withholding
$61K
About Veracyte, Inc.
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer…
Medical - Diagnostics & Research
Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works